Treatment decisions in advanced luminal breast cancer are based on clinical factors and prognostic and preventive biomarkers. Over the last 5 years, in the scenario of disease progression with CDK4/6 inhibitors, there are various treatment options available, including PI3K inhibitors, AKT inhibitors, new drug designs targeting the estrogen receptor, PARP inhibitors, and antibody-drug conjugates.
Additionally, emerging technologies such as the analysis of resistance mutations through liquid biopsy have been incorporated into routine practice and endorsed by international guidelines. During this presentation, we will discuss specific considerations that support treatment recommendations in a scenario of increasing complexity.